Abstract
Pancreas cancer is the fourth leading cause of cancer death due to the limited treatment success rate. The wide number of signalling pathway aberrations contributing to tumorigenesis, progression and drug resistance, is the main reason for unsuccessful treatments in pancreatic cancer. An additional and still under-investigated intracellular cancer target is the peroxisome proliferator activated receptor gamma (PPAR-γ). Several studies have shown the in vitro antitumor activity of PPAR-γ agonists in cancer cells but, if used in monotherapy, they were poorly effective in cancer treatment. The present review will focus on the potential therapeutic role of PPAR-γ agonists in combination with other drugs (type I interferons, gemcitabine and COX-2 inhibitors), highlighting molecular interactions and signalling pathways involved in pancreatic cancer cells. Understanding of the underlying molecular mechanisms and survival pathways activated in cancer cells should promote the development of more successful strategies based on the specific targeting of molecular pathways involved in the resistance to anti-cancer agents.
Keywords: Cancer therapy, COX-2 inhibitors, gemcitabine, interferon-β, pancreatic cancer, PPAR-γ, thiazolodinediones.
Current Cancer Drug Targets
Title:Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Volume: 13 Issue: 4
Author(s): Alessandra Dicitore, Michele Caraglia, Annamaria Colao, Silvia Zappavigna, Daniela Mari, Leo J. Hofland, Luca Persani and Giovanni Vitale
Affiliation:
Keywords: Cancer therapy, COX-2 inhibitors, gemcitabine, interferon-β, pancreatic cancer, PPAR-γ, thiazolodinediones.
Abstract: Pancreas cancer is the fourth leading cause of cancer death due to the limited treatment success rate. The wide number of signalling pathway aberrations contributing to tumorigenesis, progression and drug resistance, is the main reason for unsuccessful treatments in pancreatic cancer. An additional and still under-investigated intracellular cancer target is the peroxisome proliferator activated receptor gamma (PPAR-γ). Several studies have shown the in vitro antitumor activity of PPAR-γ agonists in cancer cells but, if used in monotherapy, they were poorly effective in cancer treatment. The present review will focus on the potential therapeutic role of PPAR-γ agonists in combination with other drugs (type I interferons, gemcitabine and COX-2 inhibitors), highlighting molecular interactions and signalling pathways involved in pancreatic cancer cells. Understanding of the underlying molecular mechanisms and survival pathways activated in cancer cells should promote the development of more successful strategies based on the specific targeting of molecular pathways involved in the resistance to anti-cancer agents.
Export Options
About this article
Cite this article as:
Dicitore Alessandra, Caraglia Michele, Colao Annamaria, Zappavigna Silvia, Mari Daniela, Hofland Leo J., Persani Luca and Vitale Giovanni, Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?, Current Cancer Drug Targets 2013; 13 (4) . https://dx.doi.org/10.2174/1568009611313040008
DOI https://dx.doi.org/10.2174/1568009611313040008 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
BRCA2 Dysfunction Promotes Malignant Transformation of Pancreatic Intraepithelial Neoplasia
Anti-Cancer Agents in Medicinal Chemistry Scaffold Vascularization: A Challenge for Three-Dimensional Tissue Engineering
Current Medicinal Chemistry Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins
Current Topics in Medicinal Chemistry Sonic Hedgehog, the Penis and Erectile Dysfunction: A Review of Sonic Hedgehog Signaling in the Penis
Current Pharmaceutical Design Metastatic Cancer Stem Cells: New Molecular Targets for Cancer Therapy
Current Pharmaceutical Biotechnology MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry Editorial: New Insights into a Classical Pathway: Key Roles of the Mevalonate Cascade in Different Diseases (Part II)
Current Molecular Pharmacology Rational Design and Development of Colon-Specific Prodrugs
Current Topics in Medicinal Chemistry The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Current Cancer Therapy Reviews Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma
Current Drug Safety Mechanisms of MDMA (Ecstasy)-Induced Oxidative Stress, Mitochondrial Dysfunction, and Organ Damage
Current Pharmaceutical Biotechnology A Single Fas Gene Mutation Changes Lupus Onset, Severity, Location, and Molecular Abnormalities in Mice
Current Molecular Medicine Amphiphilic Oligomers: A New Kind of Macromolecular Carrier of Antimitotic Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Emerging Concepts in Diabetes: Mitochondrial Dynamics and Glucose Homeostasis
Current Diabetes Reviews Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery A Three-gene-based Type 1 Diabetes Diagnostic Signature
Current Pharmaceutical Design Emerging Role of Interleukins for the Assessment and Treatment of Liver Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets